Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

34.17 +0.04 (+0.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Potentially Undervalued Stock with Strong Fundamentals
Harmony Biosciences (HRMY) shows strong growth, profitability, and financial health while trading at an attractive valuation, making it a potential pick for value investors. 
Via Chartmill
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) - A Strong Candidate for Affordable Growth Investors
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) offers strong growth, reasonable valuation, and solid financial health, making it an attractive option for investors seeking affordable growth stocks. 
Via Chartmill
Deep Dive Into Harmony Biosciences Hldgs Stock: Analyst Perspectives (13 Ratings)
Via Benzinga
Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Earnings Scheduled For May 6, 2025
Via Benzinga
Harmony Biosciences's Earnings: A Preview
Via Benzinga
Demystifying Harmony Biosciences Hldgs: Insights From 11 Analyst Reviews
Via Benzinga
Earnings Scheduled For February 25, 2025
Via Benzinga
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock
Harmony Biosciences Holdings (NASDAQ:HRMY) is a strong affordable growth stock with high growth, solid profitability, and attractive valuation. Learn why it stands out in the pharmaceutical sector. 
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock Candidate
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock Candidate 
Via Chartmill
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Uncover the potential of HARMONY BIOSCIENCES HOLDINGS, an undervalued stock. NASDAQ:HRMY maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is not too expensive for the growth it is showing.
Discover HARMONY BIOSCIENCES HOLDINGS, an undervalued growth gem. NASDAQ:HRMY is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an... 
Via Chartmill
Breaking Down Harmony Biosciences Hldgs: 13 Analysts Share Their Views
Via Benzinga
Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Friday's pre-market session: top gainers and losers
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
In the world of growth stocks, HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) shines as a value proposition.
HARMONY BIOSCIENCES HOLDINGS was identified as a growth stock that isn't overvalued. NASDAQ:HRMY is excelling in various growth indicators while maintaining a solid financial footing. 
Via Chartmill
Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors
From Harmony Biosciences Holdings, Inc.
Via Business Wire
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY): a strong growth stock preparing for the next leg up?.
Based on a technical and fundamental analysis of NASDAQ:HRMY we can say: HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands
From Harmony Biosciences Holdings, Inc.
Via Business Wire
HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Expert Outlook: Harmony Biosciences Hldgs Through The Eyes Of 11 Analysts
Via Benzinga
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), a growth stock which is not overvalued.
Discover HARMONY BIOSCIENCES HOLDINGS, an undervalued growth gem. NASDAQ:HRMY is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an... 
Via Chartmill
Harmony Biosciences to Participate in Upcoming Investor Conferences
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—it's a hidden gem with strong fundamentals and an attractive price tag.
When you look at HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Harmony Biosciences (HRMY) Q4 2024 Earnings Call Transcript
HRMY earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder
Harmony Biosciences' FDA setback for pitolisant in idiopathic hypersomnia doesn't impact its 2025 revenue outlook, with a Phase 3 trial planned for late 2025. 
Via Benzinga
Exposures Product Safety
Harmony Biosciences Crashes On Surprise Rejection For Bread-And-Butter Drug
The agency rejected the drug in the application filing stage, which is earlier than usual. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.